Pathway's New World of Hurt

Wednesday, September 28, 2011

As far as I'm able to see it, the Pathway Genomics business plan comes from the Underpants Gnomes, to wit:

  1. Make large, FDA-flaunting announcement
  2. ???
  3. Profit!

Pathway, you'll recall, was responsible for the Walgreens debacle that helped put DTCG vendors under the hot glare of the regulators. Now they're back for a repeat performance, claiming that FDA has classified their saliva collection tube as Class I, 510(k) exempt.

That might come as a surprise to other saliva collection vendors, who seem to believe that 510(k) clearance is required. That's our interpretation too.

It will be interesting to see what gets published first: the retraction or the warning letter. I expect to see one or the other pretty soon.

 

UPDATE (9/29/11) FDA weighs in: "Registration is not a classification process"

 

Tags: 510(k), Advertising & Promotion, FDA, Public Statements, Warning Letters

Share / Follow



Other Blog Authors

Dylan Reinhardt
Dave Kern
Maureen Mende
Diane Ward

Recent Blogs

The Dream of the 90s is Alive at CBER OraSure's at-home HIV test delivers on 20 years of effort
In-Vehicle Diagnostics Assessing the bold future of automotive medicine
Great New Companion Diagnostics E-Book Released Today A valuable resource in a hot, but under-informed segment of the market
Oragene Clearance Shows DNA Stabilization is Class II Clearance could have a significant impact on DTCG providers

Glossary Terms

510(k)
Class I Device
Recall